This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

For kidney transplant recipients, immunosuppression commonly consists of combination
treatment with a calcineurin inhibitor, an antiproliferative agent and a corticosteroid. Many …

The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
represents the first update to this set of recommendations since the initial set of KDIGO …

Human gastrointestinal tract is covered by a monolayer of specialized epithelial cells that
constitute a protective barrier surface to external toxic and infectious agents along with …

Background. In renal transplant (RT) recipients, treatment with enteric-coated
mycophenolate sodium (EC-MPS) improves gastrointestinal (GI) tolerability compared with …

Background Lower post-prandial glucose (PPG) and insulin (PPI) responses to foods are
associated with reduced diabetes risk and progression. Several plant extracts have been …

Importance of the field: Mycophenolic acid (MPA) therapy is a fundamental component of
most post-transplant immunosuppressive regimens. Side effects, however, are common and …

Abstract Background Gastrointestinal disorders (GDs) are common in renal transplant
recipients. The main cause of GDs seems to be the use of immunosuppressive medications …

Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both
short-and long-term outcomes following renal transplantation, but is often associated with …

Background Tacrolimus (TAC) combined with mycophenolate mofetil (MMF) is the
immunosuppressive regimen in the majority of solid organ transplant recipients …